<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27084">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02754141</url>
  </required_header>
  <id_info>
    <org_study_id>CA013-004</org_study_id>
    <secondary_id>2016-000603-91</secondary_id>
    <nct_id>NCT02754141</nct_id>
  </id_info>
  <brief_title>A Study of BMS-986179 Administered in Combination With Nivolumab in Advanced Cancers</brief_title>
  <official_title>A Phase 1/2a Study of BMS-986179 Administered in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacodynamics,
      anti-tumor activity, and pharmacokinetics of BMS-986179 when combined with nivolumab in
      patients with advanced cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events (AE), serious adverse events (SAE), AEs leading to discontinuation, and deaths</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMS-986179 enzyme assays in pre- and on-treatment biopsies</measure>
    <time_frame>Approximately 63 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMS-986179 immunohistochemistry (IHC) in pre- and on-treatment biopsies</measure>
    <time_frame>Approximately 63 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rate (PFSR)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to time of the last quantifiable concentration [AUC(0-T)]</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (T-HALF)</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective elimination half-life (T-HALFeff)</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at the end of the dosing interval (Ctau)</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration at the end of the dosing interval (Ctrough)</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT)</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss)</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index (AI)</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of terminal phase (Vz)</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of fluctuation or fluctuation index (DF)</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of positive anti-drug antibody (ADA) to BMS-986179</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of positive anti-drug antibody (ADA) to nivolumab</measure>
    <time_frame>Up to 100 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Malignant Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Combination Therapy with Monotherapy Lead-In (Dose-Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986179 leading to combination of BMS-986179 + nivolumab, dose as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy (Pharmacodynamic Sub-study)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986179 + nivolumab, dose as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort Expansion Combination Therapy (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986179 + nivolumab, dose as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986179</intervention_name>
    <description>Specified dose on specified days, intravenous (IV)</description>
    <arm_group_label>Combination Therapy with Monotherapy Lead-In (Dose-Escalation)</arm_group_label>
    <arm_group_label>Combination Therapy (Pharmacodynamic Sub-study)</arm_group_label>
    <arm_group_label>Cohort Expansion Combination Therapy (Dose Expansion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days, IV</description>
    <arm_group_label>Combination Therapy with Monotherapy Lead-In (Dose-Escalation)</arm_group_label>
    <arm_group_label>Combination Therapy (Pharmacodynamic Sub-study)</arm_group_label>
    <arm_group_label>Cohort Expansion Combination Therapy (Dose Expansion)</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Men and women at least 18 years of age

          -  Advanced solid tumors

          -  Eastern Cooperative Oncology Group (ECOG) 0-1

          -  Acceptable lab testing results

          -  Allow biopsies

        Exclusion Criteria:

          -  Central nervous system (CNS) tumors

          -  Uncontrolled or significant cardiovascular diseases

          -  Active or known autoimmune disease

          -  Organ transplant

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dung Le, Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center (Cumc)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Carvajal, Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, Pllc</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Infante, Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0007</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0006</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>April 22, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
